<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Your Brain's Backup Battery — January 18, 2026</title>

    <!-- Fonts: Editorial elegance meets technical clarity -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,400;9..144,600;9..144,700&family=Source+Sans+3:wght@400;500;600&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">

    <style>
        :root {
            /* Core palette - indigo/violet for research/science */
            --bg: #FDFBF7;
            --bg-alt: #F5F1EA;
            --text: #1A1815;
            --text-secondary: #5C564D;
            --accent: #5B4B8A;
            --accent-soft: rgba(91, 75, 138, 0.12);
            --accent-hover: #4A3D70;
            --border: #E5E0D8;
            --border-strong: #D1C9BC;

            /* Typography scale */
            --font-display: 'Fraunces', Georgia, serif;
            --font-body: 'Source Sans 3', -apple-system, sans-serif;
            --font-mono: 'JetBrains Mono', monospace;

            /* Spacing */
            --space-xs: 0.5rem;
            --space-sm: 1rem;
            --space-md: 1.5rem;
            --space-lg: 2.5rem;
            --space-xl: 4rem;
            --space-2xl: 6rem;

            /* Layout */
            --content-width: 680px;
            --wide-width: 900px;
        }

        /* Dark mode variant */
        @media (prefers-color-scheme: dark) {
            :root {
                --bg: #141210;
                --bg-alt: #1E1B18;
                --text: #F5F1EA;
                --text-secondary: #A69E93;
                --accent: #8B7BB0;
                --accent-soft: rgba(139, 123, 176, 0.15);
                --accent-hover: #9B8BC0;
                --border: #2E2A25;
                --border-strong: #3D3832;
            }
        }

        *, *::before, *::after {
            box-sizing: border-box;
        }

        html {
            font-size: 18px;
            scroll-behavior: smooth;
        }

        body {
            margin: 0;
            padding: 0;
            font-family: var(--font-body);
            font-weight: 400;
            line-height: 1.7;
            color: var(--text);
            background: var(--bg);
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
        }

        /* ========================================
           HEADER
           ======================================== */

        .header {
            padding: var(--space-lg) var(--space-md);
            border-bottom: 1px solid var(--border);
        }

        .header-inner {
            max-width: var(--content-width);
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: baseline;
        }

        .newsletter-brand {
            font-family: var(--font-display);
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
            text-decoration: none;
            letter-spacing: -0.01em;
        }

        .newsletter-date {
            font-family: var(--font-mono);
            font-size: 0.75rem;
            color: var(--text-secondary);
            letter-spacing: 0.03em;
        }

        /* ========================================
           HERO
           ======================================== */

        .hero {
            padding: var(--space-xl) var(--space-md) var(--space-2xl);
            text-align: center;
        }

        .hero-inner {
            max-width: var(--content-width);
            margin: 0 auto;
        }

        .hero-label {
            display: inline-block;
            font-family: var(--font-mono);
            font-size: 0.7rem;
            font-weight: 500;
            text-transform: uppercase;
            letter-spacing: 0.15em;
            color: var(--accent);
            background: var(--accent-soft);
            padding: 0.4em 1em;
            border-radius: 2px;
            margin-bottom: var(--space-md);
        }

        .hero-title {
            font-family: var(--font-display);
            font-size: clamp(2.2rem, 5vw, 3.2rem);
            font-weight: 700;
            line-height: 1.15;
            letter-spacing: -0.025em;
            margin: 0 0 var(--space-md);
            color: var(--text);
        }

        .hero-subtitle {
            font-size: 1.15rem;
            color: var(--text-secondary);
            max-width: 540px;
            margin: 0 auto;
            line-height: 1.6;
        }

        /* Audio Player */
        .audio-player {
            display: flex;
            align-items: center;
            gap: var(--space-sm);
            background: var(--bg-alt);
            border: 1px solid var(--border);
            border-radius: 12px;
            padding: var(--space-sm) var(--space-md);
            margin-top: var(--space-md);
            max-width: 400px;
            margin-left: auto;
            margin-right: auto;
        }
        .audio-player svg { flex-shrink: 0; color: var(--accent); }
        .audio-player audio { flex: 1; height: 36px; min-width: 0; }
        .audio-player-label { font-family: var(--font-body); font-size: 0.85rem; color: var(--text-secondary); white-space: nowrap; }

        .hero-image {
            margin-top: var(--space-xl);
            border-radius: 8px;
            overflow: hidden;
            box-shadow:
                0 4px 6px rgba(0,0,0,0.04),
                0 12px 24px rgba(0,0,0,0.06);
        }

        .hero-image img {
            width: 100%;
            height: auto;
            display: block;
        }

        /* ========================================
           CONTENT SECTIONS
           ======================================== */

        .content {
            max-width: var(--content-width);
            margin: 0 auto;
            padding: 0 var(--space-md);
        }

        .section {
            padding: var(--space-xl) 0;
            border-bottom: 1px solid var(--border);
            opacity: 0;
            transform: translateY(20px);
            animation: fadeInUp 0.6s ease forwards;
        }

        .section:nth-child(1) { animation-delay: 0.1s; }
        .section:nth-child(2) { animation-delay: 0.2s; }
        .section:nth-child(3) { animation-delay: 0.3s; }
        .section:nth-child(4) { animation-delay: 0.4s; }
        .section:nth-child(5) { animation-delay: 0.5s; }
        .section:nth-child(6) { animation-delay: 0.6s; }

        .section:last-child {
            border-bottom: none;
        }

        @keyframes fadeInUp {
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        .section-number {
            font-family: var(--font-mono);
            font-size: 0.7rem;
            font-weight: 500;
            color: var(--accent);
            letter-spacing: 0.1em;
            margin-bottom: var(--space-xs);
        }

        .section-title {
            font-family: var(--font-display);
            font-size: 1.6rem;
            font-weight: 600;
            line-height: 1.3;
            letter-spacing: -0.015em;
            margin: 0 0 var(--space-sm);
            color: var(--text);
        }

        .section-meta {
            display: flex;
            gap: var(--space-sm);
            align-items: center;
            margin-bottom: var(--space-md);
            flex-wrap: wrap;
        }

        .section-source {
            font-family: var(--font-mono);
            font-size: 0.72rem;
            color: var(--text-secondary);
            letter-spacing: 0.02em;
        }

        .section-source a {
            color: var(--accent);
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: border-color 0.2s ease;
        }

        .section-source a:hover {
            border-color: var(--accent);
        }

        .section-date {
            font-family: var(--font-mono);
            font-size: 0.72rem;
            color: var(--text-secondary);
            letter-spacing: 0.02em;
        }

        .section-date::before {
            content: "•";
            margin: 0 0.5em;
        }

        .section-body p {
            margin: 0 0 var(--space-sm);
        }

        .section-body p:last-child {
            margin-bottom: 0;
        }

        .section-body a {
            color: var(--accent);
            text-decoration: underline;
            text-decoration-color: var(--accent-soft);
            text-underline-offset: 2px;
            transition: text-decoration-color 0.2s ease;
        }

        .section-body a:hover {
            text-decoration-color: var(--accent);
        }

        .article-image {
            margin: 0 0 var(--space-md) 0;
            border-radius: 6px;
            overflow: hidden;
        }

        .article-image img {
            width: 100%;
            height: auto;
            display: block;
        }

        /* Callout boxes */
        .callout {
            background: var(--bg-alt);
            border-left: 3px solid var(--accent);
            padding: var(--space-md);
            margin: var(--space-md) 0;
            border-radius: 0 4px 4px 0;
        }

        .callout p {
            margin: 0;
            font-size: 0.95rem;
        }

        /* Code/technical snippets */
        code {
            font-family: var(--font-mono);
            font-size: 0.85em;
            background: var(--bg-alt);
            padding: 0.15em 0.4em;
            border-radius: 3px;
            color: var(--accent);
        }

        /* Charts and data visualizations */
        .chart {
            margin: var(--space-md) 0;
            padding: 0;
        }

        .chart img {
            width: 100%;
            height: auto;
            display: block;
            border-radius: 6px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.06);
        }

        .chart figcaption {
            font-family: var(--font-mono);
            font-size: 0.75rem;
            color: var(--text-secondary);
            margin-top: var(--space-xs);
            padding: 0 var(--space-xs);
            line-height: 1.5;
        }

        /* ========================================
           CLOSING / FOOTER
           ======================================== */

        .closing {
            padding: var(--space-2xl) var(--space-md);
            text-align: center;
            background: var(--bg-alt);
        }

        .closing-inner {
            max-width: var(--content-width);
            margin: 0 auto;
        }

        .closing-title {
            font-family: var(--font-display);
            font-size: 1.4rem;
            font-weight: 600;
            margin: 0 0 var(--space-sm);
        }

        .closing-text {
            color: var(--text-secondary);
            margin: 0 0 var(--space-md);
        }

        .footer {
            padding: var(--space-lg) var(--space-md);
            border-top: 1px solid var(--border);
        }

        .footer-inner {
            max-width: var(--content-width);
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: var(--space-sm);
        }

        .footer-brand {
            font-family: var(--font-display);
            font-size: 0.9rem;
            font-weight: 600;
            color: var(--text);
        }

        /* ========================================
           RESPONSIVE
           ======================================== */

        @media (max-width: 600px) {
            html {
                font-size: 16px;
            }

            .header-inner,
            .footer-inner {
                flex-direction: column;
                align-items: flex-start;
                gap: var(--space-xs);
            }

            .hero {
                padding: var(--space-lg) var(--space-md) var(--space-xl);
            }

            .hero-title {
                font-size: 1.9rem;
            }

            .section {
                padding: var(--space-lg) 0;
            }

            .section-title {
                font-size: 1.35rem;
            }
        }

        /* ========================================
           PRINT STYLES
           ======================================== */

        @media print {
            .header,
            .footer {
                display: none;
            }

            .section {
                break-inside: avoid;
            }
        }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="index.html" class="newsletter-brand">The Research Digest</a>
            <time class="newsletter-date">January 18, 2026</time>
        </div>
    </header>

    <section class="hero">
        <div class="hero-inner">
            <span class="hero-label">Alzheimer's Research</span>
            <h1 class="hero-title">Your Brain's Backup Battery</h1>
            <p class="hero-subtitle">This week in Alzheimer's research: Two major drug programs collapse while scientists discover your gut microbiome may be running the show all along. Plus, a non-invasive test that predicts cognitive decline 2.5 years out.</p>

            <div class="audio-player">
                <svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M9 18V5l12-2v13"/><circle cx="6" cy="18" r="3"/><circle cx="18" cy="16" r="3"/></svg>
                <span class="audio-player-label">Listen</span>
                <audio controls preload="metadata">
                    <source src="audio/your-brains-backup-battery.wav" type="audio/wav">
                </audio>
            </div>

            <div class="hero-image">
                <img src="images/hero-alzheimers-neural.jpg" alt="Neural pathways representing gut-brain connection in Alzheimer's research">
            </div>
        </div>
    </section>

    <main class="content">
        <!-- SECTION 1: Gut-Brain Axis (Jan 16) -->
        <article class="section">
            <span class="section-number">01</span>
            <h2 class="section-title">The Second Brain Theory Gets Real</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://news.asu.edu/20260116-gut-brain-alzheimers-link">Arizona State University</a></span>
                <span class="section-date">January 16, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-01-gut-brain.jpg" alt="Visualization of gut-brain neural highway">
            </figure>
            <div class="section-body">
                <p>For decades, Alzheimer's research fixated on the brain as both origin and battleground. New research from <a href="https://www.asu.edu/">Arizona State University</a> suggests the war may actually start in your digestive tract—years before you notice anything wrong upstairs.</p>

                <p>The study identified specific gut microbiome disruptions that precede the inflammatory cascade eventually reaching the brain. Think of it as a biological early warning system we've been ignoring: while researchers hunted for brain-based biomarkers, the gut was already sounding alarms.</p>

                <p>The implications are significant. Dietary and probiotic interventions—cheap, safe, and non-invasive—might offer a prevention window we previously thought required expensive pharmaceuticals. This isn't alternative medicine wishful thinking; it's the "body-first" hypothesis gaining hard empirical support.</p>

                <div class="callout">
                    <p><strong>The takeaway:</strong> If gut dysbiosis drives neuroinflammation, then the billion-dollar drug pipeline may be treating symptoms while ignoring the source. Diet might actually matter.</p>
                </div>
            </div>
        </article>

        <!-- SECTION 2: Whole-Brain Atrophy (Jan 14) -->
        <article class="section">
            <span class="section-number">02</span>
            <h2 class="section-title">The Hippocampus Isn't the Whole Story</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.nature.com/ncomms/">Nature Communications</a></span>
                <span class="section-date">January 14, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-02-brain-atrophy.jpg" alt="Holographic brain scan showing widespread atrophy patterns">
            </figure>
            <div class="section-body">
                <p>Memory loss isn't just about the hippocampus. A mega-analysis of over 10,000 MRI scans reveals that age-related cognitive decline correlates with structural changes across the <em>entire</em> brain—not just the memory center everyone's been watching.</p>

                <p>The research, published in <a href="https://www.nature.com/ncomms/">Nature Communications</a>, identified a non-linear pattern that should concern anyone tracking brain health: memory loss accelerates disproportionately as widespread tissue shrinkage accumulates. It's not a gradual slope—it's a cliff edge that approaches faster than linear models predicted.</p>

                <p>Perhaps most importantly for personalized medicine: genetic risk factors like <a href="https://www.alzheimers.gov/alzheimers-dementias/what-is-alzheimers/genetics">APOE4</a> were found to influence this whole-brain atrophy pattern. If you carry the gene, monitoring isolated brain regions may give false reassurance.</p>

                <figure class="chart">
                    <img src="images/chart-risk-factors.png" alt="Chart showing modifiable dementia risk factors">
                    <figcaption>Modifiable risk factors for dementia, with this week's research highlighted. Source: Lancet Commission + January 2026 studies.</figcaption>
                </figure>
            </div>
        </article>

        <!-- SECTION 3: Simufilam Discontinued (Jan 13) -->
        <article class="section">
            <span class="section-number">03</span>
            <h2 class="section-title">Simufilam: The Controversial End</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.cassavasciences.com/news-releases">Cassava Sciences</a></span>
                <span class="section-date">January 13, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-03-simufilam.jpg" alt="Empty pharmaceutical lab representing discontinued research">
            </figure>
            <div class="section-body">
                <p>The most controversial drug in Alzheimer's research is officially dead. <a href="https://www.cassavasciences.com/">Cassava Sciences</a> announced it will discontinue simufilam after both Phase 3 trials—RETHINK-ALZ and REFOCUS-ALZ—failed to meet any primary, secondary, or exploratory endpoints. Not a single one.</p>

                <p>This wasn't just another drug failure. Simufilam had been dogged by allegations of data manipulation, a citizen petition to the FDA, and a Securities and Exchange Commission investigation. True believers pointed to earlier phase results; skeptics called it too good to be true. The Phase 3 data settles the debate decisively.</p>

                <p>The company published detailed results immediately in the <a href="https://link.springer.com/journal/41999">Journal of Prevention of Alzheimer's Disease</a>—a transparency move that at least allows the field to learn from the failure rather than leaving researchers to speculate about what went wrong.</p>

                <figure class="chart">
                    <img src="images/chart-trial-outcomes.png" alt="Chart showing recent Alzheimer's drug trial outcomes">
                    <figcaption>Recent Alzheimer's drug development outcomes. Two approved treatments in 2023-2024, two major failures in January 2026.</figcaption>
                </figure>
            </div>
        </article>

        <!-- SECTION 4: Semaglutide Analysis (Jan 13) -->
        <article class="section">
            <span class="section-number">04</span>
            <h2 class="section-title">Ozempic Can't Cross the Wall</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.pharmacytimes.com/view/semaglutide-alzheimers-analysis">Pharmacy Times</a></span>
                <span class="section-date">January 13, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-04-semaglutide.jpg" alt="Blood-brain barrier blocking molecules">
            </figure>
            <div class="section-body">
                <p>The dream of repurposing <a href="https://www.novonordisk-us.com/">Novo Nordisk's</a> blockbuster weight-loss drugs for Alzheimer's hit a biological wall—literally. Post-mortem analysis of the failed EVOKE trials suggests semaglutide simply can't cross the blood-brain barrier in sufficient quantities at safe doses.</p>

                <p>The metabolic improvements were real: patients showed better glucose regulation and reduced systemic inflammation. None of it translated to neuroprotection or slowed cognitive decline. The brain remained unreached while the body improved.</p>

                <p>This doesn't end the GLP-1 story for dementia entirely. There's still a plausible case that metabolic interventions early enough—decades before symptoms—could have preventive value. But for treating established disease, <a href="https://en.wikipedia.org/wiki/GLP-1_receptor_agonist">GLP-1 agonists</a> aren't the answer. The hype cycle needs recalibration.</p>

                <div class="callout">
                    <p><strong>What this means:</strong> Metabolic health matters for brain health, but fixing metabolism after neurons start dying is too little, too late. Prevention, not treatment.</p>
                </div>
            </div>
        </article>

        <!-- SECTION 5: MCI Predictor (Jan 12) -->
        <article class="section">
            <span class="section-number">05</span>
            <h2 class="section-title">The Crystal Ball We've Been Waiting For</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://direct.mit.edu/imag">Imaging Neuroscience</a> / Brown University</span>
                <span class="section-date">January 12, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-05-mci-predictor.jpg" alt="Brain activity waves forming predictive patterns">
            </figure>
            <div class="section-body">
                <p>Researchers at <a href="https://www.brown.edu/">Brown University</a> have identified a specific pattern of electrical brain activity that predicts which patients with Mild Cognitive Impairment will progress to Alzheimer's disease—up to 2.5 years before it happens.</p>

                <p>The method uses standard EEG and imaging techniques. No spinal taps. No expensive PET scans. No invasive procedures. This is the "holy grail" that clinical trial designers have been hunting for: a way to identify patients who will actually progress, ensuring experimental drugs get tested on the right population.</p>

                <figure class="chart">
                    <img src="images/chart-mci-prediction.png" alt="Comparison of MCI-to-Alzheimer's prediction methods">
                    <figcaption>How far in advance different methods can predict MCI-to-Alzheimer's conversion. The new EEG pattern outperforms existing techniques while being less invasive.</figcaption>
                </figure>

                <p>Previous trial failures have been haunted by the inclusion problem: testing drugs on patients who were never going to progress anyway. If this biomarker validates in larger studies, it could dramatically improve the signal-to-noise ratio in future trials—and potentially salvage drugs that "failed" only because they were tested on the wrong patients.</p>
            </div>
        </article>

        <!-- SECTION 6: Sleep and Circadian Rhythms (Jan 12) -->
        <article class="section">
            <span class="section-number">06</span>
            <h2 class="section-title">Sleep Is the Cheapest Medicine</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.alzheimersresearchuk.org/news/sleep-patterns-dementia-risk">Alzheimer's Research UK</a></span>
                <span class="section-date">January 12, 2026</span>
            </div>
            <figure class="article-image">
                <img src="images/article-06-sleep.jpg" alt="Circadian rhythm visualization with sleeping figure">
            </figure>
            <div class="section-body">
                <p>A new study confirms what sleep researchers have suspected: disrupted circadian rhythms and poor sleep hygiene aren't just symptoms of aging—they're strong predictors of future dementia. And unlike your genes, you can actually do something about them.</p>

                <p>The research, supported by <a href="https://www.alzheimersresearchuk.org/">Alzheimer's Research UK</a>, found that "weak" daily patterns—where activity doesn't peak distinctly during the day—correlated with significantly higher dementia risk. The mechanism likely involves glymphatic clearance: the brain's garbage collection system that runs primarily during sleep.</p>

                <p>This is immediately actionable advice that doesn't require waiting for drug approvals or genetic interventions. Consistent sleep schedules, morning light exposure, and evening wind-down routines aren't just wellness fads—they're evidence-based risk reduction strategies that work decades before symptom onset.</p>

                <div class="callout">
                    <p><strong>Practical steps:</strong> Wake at the same time daily. Get bright light within an hour of waking. Dim lights 2 hours before bed. These simple interventions may reduce dementia risk more than any drug currently available.</p>
                </div>
            </div>
        </article>
    </main>

    <section class="closing">
        <div class="closing-inner">
            <h2 class="closing-title">The Pattern This Week</h2>
            <p class="closing-text">Two expensive pharmaceutical programs collapsed while three studies pointed toward cheaper, earlier interventions: gut health, sleep hygiene, and non-invasive biomarkers. The future of Alzheimer's treatment might not be a blockbuster drug—it might be catching the disease before it needs one. The billions spent on amyloid-targeting therapies have produced three approved treatments with modest benefits and significant side effects. Meanwhile, lifestyle interventions addressing 35% of modifiable risk factors remain underutilized. Perhaps it's time to rebalance the portfolio.</p>
        </div>
    </section>

    <footer class="footer">
        <div class="footer-inner">
            <span class="footer-brand">The Research Digest</span>
        </div>
    </footer>
</body>
</html>
